Your browser doesn't support javascript.
loading
Safety of a formulation containing chitosan microparticles with chamomile: blind controlled clinical trial.
Garbuio, Danielle Cristina; Zamarioli, Cristina Mara; Melo, Maísa Oliveira de; Campos, Patrícia Maria Berardo Gonçalves Maia; Carvalho, Emília Campos de; Freitas, Luis Alexandre Pedro de.
Afiliação
  • Garbuio DC; Universidade Anhanguera, Valinhos, SP, Brazil.
  • Zamarioli CM; Universidade de São Paulo, Escola de Enfermagem de Ribeirão Preto, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, Brazil.
  • Melo MO; Universidade de São Paulo, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Ribeirão Preto, SP, Brazil.
  • Campos PMBGM; Universidade de São Paulo, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Ribeirão Preto, SP, Brazil.
  • Carvalho EC; Universidade de São Paulo, Escola de Enfermagem de Ribeirão Preto, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, Brazil.
  • Freitas LAP; Universidade de São Paulo, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Ribeirão Preto, SP, Brazil.
Rev Lat Am Enfermagem ; 26: e3075, 2018 Nov 29.
Artigo em Inglês, Português, Espanhol | MEDLINE | ID: mdl-30517572
ABSTRACT

OBJECTIVE:

to evaluate the safety of a topical formulation containing chamomile microparticles coated with chitosan in the skin of healthy participants.

METHOD:

phase I blind, controlled, non-randomized, single-dose clinical trial with control for skin, base formulation, and formulation with microparticles. The variables analyzed were irritation and hydration by the Wilcoxon and Kruskall-Wallis tests.

RESULTS:

the study started with 35 participants with a mean age of 26.3 years. Of these, 30 (85.71%) were female, 29 (82.90%) were white skinned and 32 (91.40%) had no previous pathologies. One participant was removed from the study reporting erythema at the site of application, and four other participants for not attending the last evaluation. In the 30 participants who completed the study, the tested formulation did not cause erythema, peeling, burning, pruritus or pain; there was an improvement in cutaneous hydration in the site of application of the formulation with microparticles. In the evaluation of the barrier function, there was an increase in transepidermal water loss in all sites.

CONCLUSION:

the formulation with chamomile microparticles is safe for topical use, not causing irritation and improving skin hydration over four weeks of use. Its effects on barrier function need further investigation. No. RBR-3h78kz in the Brazilian Registry of Clinical Trials (ReBEC).
Assuntos

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Pele / Extratos Vegetais / Camomila / Quitosana Tipo de estudo: Ensaio clínico controlado Limite: Adolescente / Adulto / Feminino / Humanos / Masculino / Meia-Idade / Jovem adulto Idioma: Inglês / Espanhol / Português Revista: Rev Lat Am Enfermagem Assunto da revista: Enfermagem Ano de publicação: 2018 Tipo de documento: Artigo País de afiliação: Brasil